Biocon expands generic formulations portfolio, launches Tacrolimus capsules in US
Biocon Ltd, an innovation-led global bio pharmaceuticals company has announced the launch of Tacrolimus capsules in the US market.
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.
The launch of Tacrolimus capsules, following an approval from the US FDA in November 2020, underscores Biocon’s relentless pursuit of its mission to make affordable healthcare accessible.
Also read: Biocon drug for COVID 19 ALZUMAb® (Itolizumab) to cost Rs 7,950 per vial
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said: “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”
Biocon Limited is an innovation-led global bio pharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, bio similars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
